$12.62
$-5.19 (-27.60%)
End-of-day quote: 07/15/2022
NasdaqGM:CVAC

CureVac N.V. (CVAC)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

If you are interested in CVAC stock information, you might also be interested in competitors like NasdaqGS:TWST.

With a P/E ratio of , the stock appears relatively cheap compared to its index ^COMP at the moment.

The market capitalization of CureVac N.V. is currently at $2.36 B. This places it among the medium capitalized companies.

The book value reported in the balance sheet results in a P/B ratio of 3.39.

With one share of CureVac N.V. investors achieved a dividend of $0.00. This results in a very low dividend yield of 0.00%.

For the risk analysis, the low beta factor should be noted, which is currently at a value of 0.00. The price of the stock NasdaqGM:CVAC is therefore subject to moderate fluctuations in relation to the overall market.

54.93% of CVAC Stocks is owned by insiders.

Since not enough Wall Street analysts have published their estimates, we are unfortunately unable to provide a reliable price target for the CVAC stock.

NasdaqGM:CVAC has a 52 week range of $14.20 - $130.48 and is currently trading around $12.62.

The low short sale ratio indicated that the value might increase in the foreseeable future.

0
Underperform
1
2
3
4
5
6
7
8
9
10
1M 3M YTD 1Y 2Y 5Y 10Y 20Y
P/E Ratio
0.0
Market Cap
2.36B
LT Debt/Cap
N/A
Price-to-book Ratio
3.39
Earnings
-
Dividend
$0.00
Div Yld
0.00%
Dividend Growth
0 Years
Beta
0.00
Short Interest
3.64%
Forecast 1Y
0.00%
Analyst Price Target
$0.00
LTG 5Y
0.00%
52 week range
$14.20 - $130.48
Country